Details of the Drug

General Information of Drug (ID: DMXJ7O8)

• Drug Name: Vitamin C
• Synonyms: l-ascorbic acid; vitamin C; 50-81-7; L(+)-Ascorbic acid; Ascorbicap; Cevitamic acid; Ascoltin; Hybrin; Secorbate; Proscorbin; Lemascorb; Ascorteal; Ascorbajen; Vitascorbol; Vitamisin; Natrascorb; Citriscorb; Cescorbat; Ascorbutina; Testascorbic; Cevitamin; Cetemican; Allercorb; Vitacimin; Roscorbic; Laroscorbine; Viscorin; Redoxon; Cenetone; Cegiolan; Cebicure; Ascorvit; Viforcit; Concemin; Cevital; Cergona; Cemagyl; Cebione; Cantaxin; Ascorin; Vitacee; Vicelat; Cevimin; Cetamid; Cenolate; Celaskon; Vitacin; Adenex; Ascorb; Ascorbicab; Ascorbicin; Ascorbinsaeure; Cantan; Cebid; Cebion; Cecon; Ceglion; Celin; Cemill; Cereon; Cetebe; Cevalin; Cevatine; Cevex; Cevibid; Cevitan; Cevitex; Cewin; Ciamin; Cipca; Colascor; Cortalex; Duoscorb; Ferancee; Hicee; Magnorbin; Ribena; Scorbacid; Semidehydroascorbate; Sodascorbate; Stuartinic; Sunkist; Tolfrinic; Vitace; Xitix; Acid Ascorbic; Acide ascorbique; Acido ascorbico; Acidum ascorbicum; Acidum ascorbinicum; Antiscorbic vita min; Antiscorbic vitamin; Antiscorbutic factor; Antiscorbutic vitamin; Ascorbyl radical; Catavin C; Ce lent; Component of Cortalex; Component of Endoglobin Forte; Component of Ferancee; Davitamon C; Ferrous ascorbate; Kyselina askorbova; Kyselina askorbova [Czech]; Magnesium Ascorbicum; Monodehydroascorbic acid; Natrascorb injectable; Oral Vitamin C; Planavit C; Roscorbi c; Vicomin C; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Arco-cee; Ascoltin (TN); Ascorbic Acid, Monosodium Salt; Ascorbicap (TN); C-Level; C-Long; C-Quin; C-Span; C-Vimin; Cee-Caps TD; Cee-Vite; Cee-caps td; Cetane-Caps TC; Cetane-Caps TD; Cevi-Bid; Component of E and C-Level; IDO-C; Iron(II) ascorbate; Iron-ascorbic acid complexes; L-Ascorbic acid; L-Lyxoascorbic acid; L-Xyloascorbic acid; L-ascorbic acid; Liqui-Cee; Meri-C; Sodium Ascorbate (Ascorbic Acid); Vitamin-C; Ascorbic acid [BAN:INN:JAN]; Ascorbic acid [INN:BAN:JAN]; CE-VI-Sol; Ce-Mi-Lin; Dora-C-500; L-3-Ketothreohexuronic acid lactone; L-3-ketothreohexuronic acid; L-Ascorbic acid, free radical form; Ascor-bid; Ascorbic acid (JP15/USP/INN); Ascor-BID; L-(+)-Ascorbic Acid; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-hex-1-eofuranos-3-ulose; L-threo-hex-2-enono-1,4-lactone; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; 3-Keto-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone (enol form); [14C]ascorbic acid

Indication

Disease Entry	ICD 11	Status	REF
Vitamin C deficiency	5B56	Approved	[1], [2]
Urinary tract infection	GC08	Phase 2	[1], [3]

• Therapeutic Class: Vitamins
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 176.12
  Topological Polar Surface Area (xlogp); -1.6
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  Absorption: The absorption of drug is 70% to 90% [4]
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.05 mL/min/kg [6]
  Elimination: 25% of drug is excreted from urine in the unchanged form [7]
  Half-life: The concentration or amount of drug in body reduced by one-half in 16 days [6]
  Metabolism: The drug is metabolized via the hepatic [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 567.77191 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.26% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.35 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 333 mg/mL [7]
• Chemical Identifiers:
  Formula: C6H8O6
  IUPAC Name: (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one
  Canonical SMILES: C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O
  InChI: InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1
  InChIKey: CIWBSHSKHKDKBQ-JLAZNSOCSA-N
• Cross-matching ID:
  PubChem CID: 54670067
  ChEBI ID: CHEBI:29073
  CAS Number: 50-81-7
  DrugBank ID: DB00126
  TTD ID: D07AHW
  VARIDT ID: DR00289
  INTEDE ID: DR0144

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Collagen (CO)	TTK982E	NOUNIPROTAC	Activator	[9]
Solute carrier family 23 member 1 (SLC23A1)	TT6XAGK	S23A1_HUMAN	Modulator	[10]
Solute carrier family 23 member 2 (SLC23A2)	TTOP832	S23A2_HUMAN	Modulator	[11]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-dependent vitamin C transporter 1 (SLC23A1)	DT3KH2X	S23A1_HUMAN	Substrate	[12]
Sodium-dependent vitamin C transporter 2 (SLC23A2)	DTVY9PJ	S23A2_HUMAN	Substrate	[13]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Thiopurine methyltransferase (TPMT)	DEFQ8VO	TPMT_HUMAN	Substrate	[14]
Prolyl 4-hydroxylase alpha-1 (P4HA1)	DESO5ZY	P4HA1_HUMAN	Substrate	[15]
Prolyl 4-hydroxylase alpha-2 (P4HA2)	DE5EGK0	P4HA2_HUMAN	Substrate	[15]
HIF-prolyl hydroxylase 2 (EGLN1)	DEWO724	EGLN1_HUMAN	Substrate	[16]
Prolyl 4-hydroxylase alpha-3 (P4HA3)	DE2L4RX	P4HA3_HUMAN	Substrate	[17]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Vitamin C (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sucralfate	DMP9HBO	Moderate	Altered absorption of Vitamin C caused by Sucralfate.	Acne vulgaris [ED80]	[33]
Ephedrine	DMMV0KW	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Vitamin C caused by Ephedrine mediated altered urine pH.	Asthma [CA23]	[34]
Lisdexamfetamine	DM6W8V5	Moderate	Decreased absorption of Vitamin C due to altered gastric pH caused by Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[35]
Amphetamine	DMSZQAK	Moderate	Decreased absorption of Vitamin C due to altered gastric pH caused by Amphetamine.	Attention deficit hyperactivity disorder [6A05]	[35]
Pseudoephedrine	DMIVJ0D	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Vitamin C caused by Pseudoephedrine mediated altered urine pH.	Breathing abnormality [MD11]	[34]
Propranolol	DM79NTF	Minor	Altered absorption of Vitamin C caused by Propranolol.	Migraine [8A80]	[36]
Dextroamphetamine	DMMIHVP	Moderate	Decreased absorption of Vitamin C due to altered gastric pH caused by Dextroamphetamine.	Narcolepsy [7A20]	[35]
Benzphetamine	DMIJATC	Moderate	Decreased absorption of Vitamin C due to altered gastric pH caused by Benzphetamine.	Obesity [5B80-5B81]	[35]
Methamphetamine	DMPM4SK	Moderate	Decreased absorption of Vitamin C due to altered gastric pH caused by Methamphetamine.	Pain [MG30-MG3Z]	[37]
Mexiletine	DMCTE9R	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Vitamin C caused by Mexiletine mediated altered urine pH.	Ventricular tachyarrhythmia [BC71]	[38]
Flecainide	DMSQDLE	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Vitamin C caused by Flecainide mediated altered urine pH.	Ventricular tachyarrhythmia [BC71]	[39]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4781).
• [2] Vitamin C: update on physiology and pharmacology. Br J Pharmacol. 2009 Aug;157(7):1097-110.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] BDDCS applied to over 900 drugs
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009 May;15(2):214-7.
• [10] Decreased expression of the vitamin C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr. 2002 Feb;87(2):97-100.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1042).
• [12] A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999 May 6;399(6731):70-5.
• [13] Molecular characterization and transcriptional regulation of the sodium-dependent vitamin C transporter genes (slc23a1 and slc23a2) in a teleost fish, the Senegalese sole (Solea senegalensis). Comp Biochem Physiol B Biochem Mol Biol. 2012 Mar;161(3):208-18.
• [14] Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
• [15] Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
• [16] Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003 Aug 15;278(33):30772-80.
• [17] Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem. 2003 Nov 28;278(48):47685-93.
• [18] Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
• [19] Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
• [20] Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
• [21] The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
• [22] Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
• [23] Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
• [24] Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
• [25] Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
• [26] Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
• [27] Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
• [28] Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36.
• [29] A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999 May 6;399(6731):70-5.
• [30] Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2.
• [31] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [32] Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2002 Sep;27(5):788-98.
• [33] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [34] Brater DC, Kaojarern S, Benet LZ, et al "Renal excretion of pseudoephedrine." Clin Pharmacol Ther 28 (1980): 690-4. [PMID: 7438686]
• [35] Product Information. Dexedrine (dextroamphetamine) SmithKline Beecham, Philadelphia, PA.
• [36] Gonzalez JP, Valdivieso A, Calvo R, Rodriquezsasiain JM, Jimenez R, Aguirre C, Dusouich P "Influence of vitamin c on the absorption and first pass metabolism of propranolol." Eur J Clin Pharmacol 48 (1995): 295-7. [PMID: 7589058]
• [37] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
• [38] Mitchell BG, Clements JA, Pottage A, Prescott LF "Mexiletine disposition: individual variation in response to urine acidification and alkalinisation." Br J Clin Pharmacol 16 (1983): 281-4. [PMID: 6626420]
• [39] Hertrampf R, Gundert-Remy U, Beckmann J, et al "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991): 61-3. [PMID: 1782979]